Topoisomerase II inhibitors etoposide and doxorubicin induced rearrangement and fusion of AML1 gene.
- Author:
Zhi-jian XIAO
1
Author Information
- Publication Type:Journal Article
- MeSH: Apoptosis; drug effects; Base Sequence; Blotting, Southern; Cell Survival; drug effects; Core Binding Factor Alpha 2 Subunit; DNA, Neoplasm; genetics; DNA-Binding Proteins; genetics; Doxorubicin; pharmacology; Etoposide; pharmacology; Gene Rearrangement; drug effects; HL-60 Cells; Humans; K562 Cells; Molecular Sequence Data; Oncogene Proteins, Fusion; genetics; Proto-Oncogene Proteins; genetics; RNA, Neoplasm; genetics; RUNX1 Translocation Partner 1 Protein; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Nucleic Acid; Topoisomerase II Inhibitors; Transcription Factors; genetics
- From: Chinese Journal of Hematology 2003;24(12):621-623
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the relationship between topoisomerase II inhibitors and t(8;21) chromosomal translocation.
METHODSThe rearrangements of AML1 and ETO genes were detected by Southern Blot and the AML1-ETO fusion gene by nested RT-PCR combined with sequencing in K562 cells treated with etoposide (Vp16) and doxorubicin (DOX).
RESULTSThe rearrangements of AML1 gene were detectable after DOX treatment at concentrations of 10, 50 and 100 micro mol/L for 16 h, AML1-ETO fusion gene appeared after 50 micro mol/L DOX treatment for 48 h.
CONCLUSIONInduction of AML1 gene rearrangement and fusion by topoisomerase II inhibitors, represents one of the molecular mechanisms of t(8;21) chromosomal translocation.
